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To develop a European surveillance protocol for 
Clostridium difficile infection (CDI), existing national 
CDI surveillance systems were assessed in 2011. 
A web-based electronic form was provided for all 
national coordinators of the European CDI Surveillance 
Network (ECDIS-Net). Of 35 national coordinators 
approached, 33 from 31 European countries replied. 
Surveillance of CDI was in place in 14 of the 31 coun-
tries, comprising 18 different nationwide systems. 
Three of 14 countries with CDI surveillance used public 
health notification of cases as the route of reporting, 
and in another three, reporting was limited to public 
health notification of cases of severe CDI. The CDI def-
initions published by the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) and 
the European Centre for Disease Prevention and 
Control (ECDC) were widely used, but there were dif-
fering definitions to distinguish between community- 
and healthcare-associated cases. All CDI surveillance 
systems except one reported annual national CDI rates 
(calculated as number of cases per patient-days). 
Only four surveillance systems regularly integrated 
microbiological data (typing and susceptibility test-
ing results). Surveillance methods varied consider-
ably between countries, which emphasises the need 
for a harmonised European protocol to allow consist-
ent monitoring of the CDI epidemiology at European 
level. The results of this survey were used to develop 
a harmonised EU-wide hospital-based CDI surveillance 
protocol. 
Introduction
Since 2000, a considerable increase in the number of 
Clostridium difficile infections (CDIs) leading to sub-
stantial morbidity, mortality and attributable costs has 
been observed, at least in North America and Europe 
[1]. Changes in the epidemiology of CDI have been 
mainly attributed to the emergence of a new hyper-
virulent strain called PCR ribotype 027, causing numer-
ous outbreaks in North America and Europe [2,3] and, 
to a lesser extent, PCR ribotype 078 [1,4,5]. In addi-
tion, patients not previously considered to be at risk 
for the disease (e.g., without recent antibiotic therapy 
or hospitalisation) have also been described [1,6-8]. 
The European CDI study (ECDIS), initiated and funded 
by the European Centre for Disease Prevention and 
Control (ECDC), showed that the incidence of CDI varied 
from hospital to hospital [9]. In 2008, a weighted mean 
incidence of 4.1 cases (range: 0.0–36.3) per 10,000 
patient-days per hospital reported by the ECDIS study 
was almost 70% higher than that reported in a previ-
ous European surveillance study in 2005 (2.45 cases 
per 10,000 patient-days per hospital, range: 0.13–7.1) 
[9,10]. ECDIS also revealed the contribution of strains 
other than PCR ribotype 027 and that some of these 
strains, notably PCR ribotypes 015, 018 and 056, could 
cause severe CDI.
In response to the emerging problems associated with 
C. difficile, an ECDC working group published back-
ground information about the changing epidemiology 
of CDI, CDI case definitions and surveillance recommen-
dations [2]. To support European Union (EU)/European 
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Table
Characteristics of European Clostridium difficile infection surveillance systems, 2011 (18 surveillance systems from 14 
countries)
Country Name Participants General remarks Epidemiological data Microbiological data
Austria No name All H/L/G
M 
C + P 
Lb + Cb 
only sevCDI
Total number 
CDI-days
RTcp 
AST
Belgium National Surveillance of Infections in Hospitals (NSIH) 110 H
M 
P 
Cb 
Periodic  
(6 months a year)
HA-CDI: 
I (1,000 pa/6 months) 
Id (10,000 pd/6 months) 
Severe CDI: 
ICU-adm/death within  
30 days related to CDI
TcdT (fp/sevCDI /ob) 
AST (fp/sevCDI /ob)
Bulgaria BGCDISS 6 H/3 L
V 
C + P 
Lb + Cb
HA-CDI: 
I (10,000 pa) 
Id (10,000 pd)
RTcp 
No AST
Denmark Surveillance of epidemic hypervirulent CD in Denmark 13 H/13 L
V 
C + P 
Lb
I (number of episodes/region) RTag (sevCDI + MoxR)/ob) AST
Finland-1 National Infectious Diseases Register All L
M 
C + P 
Lb
I (100,000 inh) RTag (sevCDI/ob) No AST
Finland-2 Finnish Hospital Infection Programme (SIRO) 12 H
V 
C + P 
Cb
HA-CDI: 
I (100 pa) 
Id (1000 pd) 
Severe CDI: 
ICU-adm/surgery/ death within 30 
days related to CDI
None
Finland-3 National Hospital Discharge Register (HILMO) 57 H
M 
C (retrosp.) 
ICD 10-based
I (CDI hospitalisations/ 
100,000 inh) None
France Healthcare acquired Infections Early warning and Response system 100 H/115 L/ 10 N
M 
C + P 
Cb 
only sevCDI/ob
Severe CDI: 
Total number 
I (1,000 pa) 
Id (10,000 pd)
RTag (sevCDI/ob) 
AST (sevCDI/ob)
Germany-1 CDAD-KISS 126 H
V 
C + P 
Cb
HA-CDI/severe CDI: 
I (100 adm) 
Id (1,000 pd)
None
Germany-2 SurvNet About 2000 H
M 
C + P 
Cb 
only sevCDI/ 
ribotype 027
Severe CDI: 
Total number 
I (100,000 inh/ 
ICU-adm/surgery/ 
death within 30 days 
related to CDI)
RTcp (sevCDI/ob) 
No AST
Hungary Epidemiological Control System and Information System (EFRIR) 35 H / 14 L
M 
C + P 
Lb + Cb
Total number RTag (sevCDI/ob) No AST
Ireland-1 Notifiable C. difficile Surveillance 
48 H/37 L / all 
G from 8 public 
health regions
M 
C + P 
Cb
I (100,000 inh) None
Ireland-2 C. difficile Enhanced Surveillance 34 H/34 L
V 
C + P 
Cb
HA-CDI:  
Id (10,000 pd) 
Severe CDI: 
ICU-adm/ 
surgery related to CDI
None
The 
Netherlands Sentinel surveillance of C. difficile 19 H/19 L
V 
C + P 
Lb + Cb
HA-CDI: 
I (CDI cases/pa) 
Id (CDI cases/pd)
RTag (fp) 
No AST
Sweden National Laboratory-based CD Surveillance System 20 L
V 
C + P 
Lb
Total number RTac (fp/sevCDI /ob) AST (fp)
UK-England HCAI Data Capture System
167 NHS Acute 
Trusts with 1–2 H 
each
M 
C + P 
Lb
All types of CDI: 
Id (adm > 65 y/1,000 pd) 
HA-CDI: 
Id (cases > 2 y/10,000 pd) 
Severe CDI: 
Death within 30 days  
related to CDI
RTca 
AST (fp)
UK-Northern 
Ireland
Enhanced HCAI Web-based 
Surveillance System
28 H/ 5 L/ 358 GP / 
240 N / 237 R
M 
C + P 
Lb
HA-CDI and CA-CDI: 
Total number 
Id (1,000 pd)
RTcp/no AST
UK-Scotland Scottish Mandatory Surveillance Programme for CDI
23 L and 14 NHS 
health boards 
including H/N/G
M 
C + P 
Lb + Cb
HA-CDI: 
Id (cases ≥ 15 y/1000 pd)
RTag (fp/sevCDI/ob) 
AST (fp/sevCDI/ob)
ac: acrylamide; adm: admissions; ag: agarose; AST: antimicrobial susceptibility testing; C: continuous; CA: community associated; cp: capillary; Cb: case-based; CD; 
Clostridium difficile; CDI: Clostridium difficile infection; fp: fixed proportion; G: general practioners; H: hospitals; HA: healthcare associated; I: incidence; ICD-10: 
International Statistical Classification of Diseases 10th revision; ICU: intensive-care unit; Id: incidence density; inh: inhabitants; L: laboratories; Lb: laboratory-based; M: 
mandatory; MoxR: moxifloxacin resistance; N: nursing homes; ob: outbreaks; pa: patient admissions; pd: patient-days; R: residential homes; retrosp.: retrospective; RT: 
ribotyping; sevCDI: severe CDI; TcdC: typing of the tcdC gene; UK: United Kingdom; V: voluntary; y: years.
a Iceland and UK-Wales did not reply to the web-based questionnaire.
b Some countries had more than one surveillance system in parallel. Where relevant, they are shown with the suffixes -1, -2 and -3.
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Economic Area (EEA) Member States in increasing 
their capacity for CDI surveillance, ECDC also initiated 
and funded a new project – ECDIS-Net – to develop a 
European surveillance protocol and enhance laboratory 
capacity for diagnosis and typing of C. difficile in EU/
EEA Member States.
In 2011, a survey of existing CDI surveillance systems 
in European countries was performed as part of the 
ECDIS-Net project. The results of this survey, pre-
sented here, were later used to develop a standardised 
pan-European CDI surveillance protocol, which was 
tested in a three-month pilot study in 2013 [11]. Data 
collection in the ECDC-coordinated Europe-wide hospi-
tal-based CDI surveillance, using a finalised version of 
this piloted protocol, began on 1 January 2016 [12].
Methods
National coordinators for this study were identified 
through the members of ECDC’s Healthcare-Associated 
Infections surveillance Network (HAI-Net) and via 
representatives for the ECDIS study [9]. A link to a 
web-based questionnaire was sent to these national 
coordinators to assess the characteristics of existing 
CDI surveillance systems in European countries. If the 
national coordinators indicated that CDI was under 
surveillance in their country, the surveillance protocols 
were requested and used to augment the information 
obtained via the questionnaire. Information on the 
national CDI surveillance systems was entered using a 
web-based electronic form designed for the purpose of 
this study.
Results
Between 6 June and 15 July 2011, 33 of the 35 national 
coordinators approached from 31 European countries 
responded to the web-based questionnaire (Iceland 
and Wales did not respond). Four surveillance systems 
were excluded from further analysis, as they were 
not ongoing, comprehensive nationwide surveillance 
systems, i.e. they were completed one-off studies 
(two studies from Spain), only regional (Switzerland) 
or focused only on outbreaks (one system of the 
Netherlands). In 14 countries, the national coordina-
tors indicated that surveillance of CDI was in place. Of 
these, surveillance protocols were available from 10 
surveillance systems. Thus, 18 CDI surveillance sys-
tems from 14 European countries (Austria, Belgium, 
Bulgaria, Denmark, Finland, France, Germany, Hungary, 
Ireland, the Netherlands, Sweden and three countries 
of the United Kingdom (UK), England, Northern Ireland 
and Scotland) remained available for analysis. Of the 
18 surveillance systems, all but one reported national 
CDI rates annually.
General characteristics of C. difficile infection 
surveillance systems
An overview of the European CDI surveillance systems 
is given in the Table. In summary, 11/18 surveillance 
systems used mandatory reporting and seven used vol-
untary reporting of cases. The majority (16/18) of the 
surveillance systems were continuous and prospec-
tive, one was periodical and prospective (Belgium), 
and one was retrospective (Finland-3). In three coun-
tries (Germany, Ireland, the Netherlands), two surveil-
lance systems were run in parallel, (shown with the 
suffixes -1 and -2). In Finland, there were three parallel 
systems (Finland-1, -2 and -3). Parallel systems were 
also in place in the three parts of the United Kingdom 
that took part in the survey (England, Northern Ireland 
and Scotland). In Finland, Germany and Ireland, one 
surveillance system was limited to (legally required) 
public health notification of CDI cases, whereas addi-
tional systems collected laboratory-based data and 
enhanced epidemiological data on a voluntary basis. 
Public health notification of CDI was also carried out in 
Austria, Denmark and Hungary.
In Austria, France and Germany-2, surveillance of CDI 
targeted severe cases only. All surveillance systems 
included CDI in hospitalised patients, but 10/18 sys-
tems also included patients with community-acquired 
CDI. CDI case ascertainment was case-based (including 
clinical evaluation) in 7/18 systems, laboratory-based 
(relying on positive test results for toxin-producing C. 
difficile) in 5/18 systems or a combination of both in 
an additional 5/18 surveillance systems. Only Finland-3 
used the International Statistical Classification of 
Diseases 10th revision (ICD-10)-based discharge cod-
ing [13] to find cases of CDI.
Definitions of C. difficile infection
The definitions used for CDI surveillance are summa-
rised in the Box .
The majority (12/18) of the surveillance systems used 
the ECDC and CDC case definition of CDI [2,14], 4/18 
used other definitions and 2/18 did not use a specific 
case definition (but relied instead on the diagnosis of 
the attending physician and a positive laboratory test 
result for toxigenic C. difficile). More detailed defini-
tions for community-associated CDI, community-onset 
of healthcare-associated CDI and healthcare-onset of 
healthcare-associated CDI were used by 9/18 (ECDC 
definition: 7/9, other definitions: 2/9). Definitions dif-
fering from ECDC’s for community-associated CDI, 
community-onset healthcare-associated CDI and 
healthcare-onset healthcare-associated CDI used a 
time point of ≥ 72 hours or > 3 days (i.e. on or after day 4 
of admission) instead of ≥ 48 hours between admission 
and onset of symptoms to distinguish between commu-
nity- and healthcare-associated CDI.
In 13/18 surveillance systems, there was a definition 
for severe cases of CDI (ECDC definition: 5/13, other 
definitions: 8/13) and in 11/18 systems, there was also 
a definition for recurrence of CDI (ECDC definition: 
9/11, other definitions: 2/11). Definitions differing from 
ECDC’s definition for severe/complicated course of 
CDI used additional criteria such as bloody diarrhoea, 
temperature > 38.5 °C, white cell count > 15 × 109/L, 
decreased kidney function or hypo-albuminaemia (< 30 
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g/L). Definitions differing from those used by ECDC 
for recurrent CDI used a time lapse of between two 
and four weeks after the previous onset to distinguish 
between different episodes of CDI.
Collection of C. difficile infection surveillance 
data
In 5/18 surveillance systems, data collection was done 
only by laboratories, in 7/18 only by infection control 
teams, and in 5/18 by both. One surveillance system 
used hospital administration data only (Finland-3). 
In 8/18 surveillance systems, case-based data were 
collected by healthcare personnel (in 7/8 in combina-
tion with the infection control teams). In addition, gen-
eral practitioners were engaged in surveillance data 
collection in Austria and UK-Scotland, as were public 
health doctors in Ireland-1. Only 3/18 surveillance sys-
tems relied solely on laboratory tests positive for CDI 
without additional patient data (Denmark, Finland-1, 
Sweden). 
The collected data were pooled nationwide in 11/18 
surveillance systems (Belgium, Bulgaria Finland-1, 
Finland-3, France, Hungary, Ireland-1, Ireland-2, 
CDI case  
A patient to whom one or more of the following criteria applies:  
1.      diarrhoeal stools or toxic megacolon AND a positive laboratory assay for C. difficile TcdA and /or TcdB in stools or a toxin-producing C. 
difficile organism detected in stool via culture or other means; 
2.      pseudomembranous colitis revealed by lower gastrointestinal endoscopy; 
3.      colonic histopathology characteristic of CDI (with or without diarrhoea) on a specimen obtained during endoscopy, colectomy or 
autopsy.
Differing definitions: 
Finland-1: Detection of C. difficile organism/DNA/RNA/toxin in a clinical sample. 
Finland-3: International Classification of Diseases (ICD)-10 codes A04.7 and K52.8 specific for Clostridium difficile-associated disease. 
UK-England: Diagnoses on the basis of tests for C. difficile toxins A and B on diarrhoeal stool samples. Positive results on the same patient 
within 28 days of the first specimen are regarded as a single episode. All cases are reported regardless of location of the patient at the time 
the specimen was taken, i.e. regardless of whether the patient was in a hospital or another setting. Diarrhoeal stools are defined as ‘those 
that take the shape of their container’. One (unexplained) diarrhoeal episode is sufficient to qualify for a diagnosis of CDI if the laboratory 
test is supportive. 
UK-Northern Ireland: A patient aged two years and over from whom a diarrhoeal specimen is tested positive for C. difficile.
Community-associated CDI  
Onset of CDI outside a healthcare facility (HCF) or within 48 hours following admission to a healthcare facility without residence in/
discharge from a healthcare facility within the previous 12 weeks. 
Differing definitions: 
Finland-2 and Germany-1: Onset of CDI in an outpatient or inpatient within 72 hours after admission to the facility.
Community-onset of healthcare-associated CDI  
Onset of CDI in the community within 4 weeks following discharge from a healthcare facility. 
Healthcare-onset of healthcare-associated CDI  
Onset of CDI at least 48 hours (> 48 hours) following admission to a healthcare facility 
Complicated course of CDI ( severe CDI case)  
A patient to whom any of the following criteria applies:  
1.      admission to a healthcare facility for treatment of community-associated CDI; 
2.      admission to an intensive-care unit for treatment of CDI or its complication (e.g. for shock requiring vasopressor therapy); 
3.      surgery (colectomy) for toxic megacolon, perforation or refractory colitis; 
4.      death within 30 days after diagnosis, if CDI is either the primary or a contributive cause.
Differing definitions: 
Austria: CDI requiring admission to an intensive-care unit/CDI requiring surgery/fatal cases of CDI. 
Germany: Instead of 1: Readmission because of recurrent CDI (points 2–4 as above) 
France: In addition: white cell count > 20 × 103/mm3. 
Hungary: Death linked to CDI (based on death register). 
Ireland-2: 1. Admission to an intensive care unit for treatment of CDI or its complication (e.g. for shock requiring vasopressor therapy) and/
or 2. surgery (colectomy) for toxic megacolon, perforation or refractory colitis. 
The Netherlands: 1. Bloody diarrhoea and/or 2. pseudomembranous colitis and/or 3. diarrhoea in combination with dehydration and/or 
hypo-albuminaemia (< 30 g / L) 4. temperature > 38 °C and white cell count > 15 × 109/L. 
UK-England: Temperature > 38.5 °C, white cell count > 15 × 109/L, decreased kidney function, or evidence of colitis. 
UK-Scotland: In addition: Endoscopic diagnosis of pseudomembranous colitis (with or without toxin confirmation) persisting CDI where the 
patient has remained symptomatic and toxin positive despite two courses of appropriate therapy.
Recurrent CDI  
An episode of CDI that occurs  > 2 weeks and ≤ 8 weeks following the onset of a previous episode. 
Differing definitions: 
UK-England: A positive specimen taken more than 28 days after the initial specimen is considered a new CDI episode. 
UK-Scotland: A new episode is defined as one occurring more than 28 days after the previous onset.
CDI: Clostridium difficile infection; UK: United Kingdom.
a Some countries had more than one surveillance system in parallel. 
Source: [2,14]. Surveillance system-specific definitions: this study.
Box
Definitions, including surveillance system-specific definitionsa, for surveillance of Clostridium difficile infections
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Sweden, UK-Northern Ireland and UK-Scotland), per 
district or health board in 9/18 systems (Austria, 
Denmark, Finland-1, Finland-3, France, Germany-2, 
Ireland-1, UK-Northern Ireland and UK-Scotland), 
per healthcare facility in 9/18 systems (Belgium, 
Bulgaria, Finland-2, France, Germany-1, Ireland-2, 
the Netherlands, UK-England, UK-Northern Ireland) 
and per unit within a healthcare facility in 2/18 sys-
tems (Finland-2, UK-Northern Ireland). In Finland-3 
and Sweden, the collected data were also pooled per 
laboratory. Data about the size or type of the reporting 
healthcare facility were collected in 12/18 CDI surveil-
lance systems, but not in the remaining six systems 
(Austria, Denmark, Finland-1, Germany-2, Hungary, 
Sweden). In 8/18 surveillance systems, even the spe-
ciality of the reporting unit or department was known.
Most of the surveillance systems collected patient 
data: age and sex of CDI cases were reported in 16/18 
surveillance systems, the date of onset of CDI in 13/18 
systems and the date of admission in 11/18 systems. 
Only one surveillance system did not collect any patient 
data (Germany-1). Data about the history of CDI cases 
were collected in 6/18 surveillance systems (number 
of previous hospital admissions: 2/6, number of previ-
ous episodes of CDI: 4/6; recurrent CDI: 5/6) and data 
about the outcome of CDI (death within 30 days) were 
collected in 5/18 systems.
Reporting of C. difficile infection surveillance 
data
CDI surveillance results were periodically reported in 
16/18 surveillance systems (ranging from daily reports 
in UK-Northern Ireland to annual reports in 9/18 sys-
tems); only 2/18 surveillance systems did not report the 
results at regular intervals (Finland-3, Germany-2). All 
18 surveillance systems published their reports nation-
ally, but in 6/18 and 3/18 surveillance systems, there 
were additional regional and local reports, respec-
tively. Most (12/18) of these reports were available 
to the public and healthcare professionals; only 4/18 
and 2/18 surveillance systems published reports that 
solely targeted healthcare professionals or the pub-
lic, respectively. Surveillance results were stratified 
in 8/18 surveillance systems, mostly by geographical 
region (4/8) or type of healthcare facility (4/8). More 
details, including denominators and calculated CDI 
rates, are given in the Table.
Typing
Typing of C. difficile was performed by national refer-
ence laboratories in 13 European countries with CDI 
surveillance, PCR ribotyping (either agarose: 8/13, 
acrylamide: 1/13 or capillary gel-based: 4/13) being 
the preferred method. Only one reference laboratory 
also used tcdC typing (Belgium). For the purposes of 
surveillance, typing was done in 13/18 European sur-
veillance systems with varying criteria for submitting 
strains for further typing: severe CDI (9/13), outbreaks 
(7/13), isolates resistant to moxifloxacin (Denmark) or a 
more systematic sampling design selecting (4/13), e.g. 
the first five strains of each semester, i.e. each half of 
the year (Belgium), all strains of selected calendar peri-
ods (Sweden, UK-Scotland) or selected hospitals (the 
Netherlands). An overview is given in the Table. A more 
detailed analysis was performed by another ECDIS-
Net survey in 2011 and 2014 of diagnostic and typing 
capacity for CDI in Europe: the results of which are also 
reported in this issue [15].
Susceptibility testing
There were no official recommendations for routine 
susceptibility testing of C. difficile isolates in any of 
the European countries taking part in ECDIS-Net, but 
susceptibility testing results were included in 7/18 CDI 
surveillance systems analysed. Conditions leading to 
susceptibility testing were the surveillance of antimi-
crobial resistance itself (5/7), severe CDI cases (4/7) or 
outbreaks of CDI (3/7).
Discussion
This survey showed that 14 of 31 European countries 
surveyed conducted some kind of CDI surveillance in 
2011. The majority of the 18 existing European nation-
wide CDI surveillance systems were continuous and 
prospective, and captured CDI cases by standardised 
case definitions targeting the clinical symptoms of CDI 
and/or laboratory diagnosis of CDI, and all of them 
included CDI in hospitalised patients. However, there 
were interesting differences between these systems. In 
11/18 of European countries with CDI surveillance, sur-
veillance was mandatory, either by mandatory report-
ing of laboratory and/or clinically confirmed cases or 
by public health notification of CDI. Whether surveil-
lance should be based on mandatory or voluntary 
reporting of confirmed cases is still under discussion 
[16-18]. Opponents of mandatory reporting argue that 
especially in combination with public reporting of sur-
veillance results and financial penalties, it may lead to 
systematic under-reporting of cases. 
An important issue for surveillance purposes is the def-
inition of CDI cases. These definitions should be valid, 
specific, easily understood, generally applicable and 
meet the requirements of different clinical settings, 
ideally across borders. Moreover, they should allow 
the comparison of local, regional, national and interna-
tional infection rates [19]. The definitions proposed by 
the study group for C. difficile of the European Society 
of Clinical Microbiology and Infectious Diseases 
(ESCMID) and ECDC [2] are in agreement with those 
of the United States Centers for Disease Control and 
Prevention (CDC) [2,14]. Most of the European CDI sur-
veillance systems adhere to these definitions, but dif-
ficulties are encountered in differentiating between 
community- and healthcare-associated cases of CDI. 
Some surveillance systems do not make any distinc-
tion between the two types of cases (for instance, 
when only laboratory data are used), while others 
use different time points for differentiating between 
the two. Stratification of community-associated and 
healthcare-associated CDI cases may permit recogni-
tion of changes in epidemiology, e.g. an increase in the 
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number of community-associated cases of CDI possibly 
caused by ’hypervirulent’ C. difficile strains [1,20,21]. 
For feasibility reasons, the definitions of community- 
and healthcare-associated cases of CDI could be sim-
plified, e.g. by adjusting the threshold time between 
the two types of cases to three days or later instead of 
48 hours. However, regardless of the threshold used, 
variable proportions of CDI cases defined as com-
munity-associated CDI cases may in fact be linked to 
recent hospitalisation.
In order to meet the ECDC CDI case definitions, most 
surveillance systems used laboratory reporting and 
identification of CDI cases by attending healthcare 
personnel and/or infection control practitioners; few 
relied solely on laboratory test results. Only one of the 
Finnish surveillance systems used ICD-10 coding of CDI 
supplied by hospital administrations. In comparison 
with surveillance using CDI case definitions, surveil-
lance using ICD coding has shown to be less sensitive 
[22,23]. In Finland, three different surveillance systems 
for CDI are run in parallel and so may compensate for 
their respective limitations.
All surveillance systems reporting hospital-associated 
CDI cases express CDI rates as incidence rate (per num-
ber of patient admissions within a given surveillance 
period) or incidence density (per number of patient-
days). However, different orders of magnitude are used 
(100 or 1,000 admissions and 1,000 or 10,000 patient-
days). Apart from that, surveillance systems only 
reporting the total number (i.e. community-associated 
and hospital-associated combined) of CDI cases mostly 
calculate the incidence per number of inhabitants; only 
a few exceptions just give the cumulative number of 
CDI cases. According to published recommendations 
and for better comparison, the incidence density of 
healthcare-associated and community-associated CDI 
should be expressed per 10,000 patient-days and 
100,000 inhabitants, respectively [14,19].
More than half of the European CDI surveillance sys-
tems presented their findings pooled, i.e. without any 
further stratification. Unfortunately, only a few surveil-
lance systems provided sender-specific analyses. This 
would, however, be very important to inform interven-
tions at local level and may help to reduce infection 
rates [24].
Microbiological data may be an important supplement 
to epidemiological surveillance data and allow deeper 
insights into epidemiological changes. In our survey, 
however, strain typing and susceptibility testing were 
mainly restricted to outbreaks of CDI or severe cases of 
CDI; only a few surveillance protocols included typing 
or susceptibility testing on a regular basis. Although 
lacking the discriminatory power to study outbreaks, 
PCR ribotyping is the most adopted C. difficile typ-
ing methodology in European reference laboratories. 
International standardisation of ribotyping methods 
would allow comparability and reproducibility between 
countries. Capillary-based ribotyping offers the oppor-
tunity to achieve these aims, as results are easier to 
interpret and to exchange than those of conventional 
agarose-based ribotyping [25-27].
The main limitations of microbiological testing for C. 
difficile are financial, and shipment of strains to refer-
ence laboratories for typing may be hampered by the 
fact that many laboratories perform toxin testing alone 
and do not culture C. difficile.
Published recommendations of ECDC and the United 
States Centers for Disease Control and Prevention 
(CDC) are that CDI surveillance should be conducted for 
at least all inpatients to monitor healthcare-associated 
CDI, and healthcare-associated CDI rates should be 
expressed as number of cases per 10,000 patient-days 
[2,14]. A standardised European CDI surveillance pro-
tocol should be used to allow meaningful intercountry 
comparisons of CDI incidence rates and for follow-up 
of the epidemiology of CDI at European level. Special 
emphasis should be given to the harmonisation of 
definitions of community-associated and healthcare-
associated CDI, inclusion criteria for patients and CDI 
cases, criteria for typing C. difficile strains, denomina-
tor data, epidemiological case-based data and case-
finding methods. In order to integrate microbiological 
test results into CDI surveillance, more frequent culture 
of C. difficile is required, and typing methods should 
be standardised. Harmonised systematic surveillance 
at national and European level is more likely to facili-
tate the identification of epidemiological changes and 
the optimal control of CDI. As a result of this survey, 
ECDC published a harmonised EU/EEA-wide hospital-
based CDI surveillance protocol in May 2015 [12].
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